Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
| Autor: | Jian-fa Shen, Chunwei Xu, Xue-ping Lin, Kai-qi Du, Hua-Fei Chen, Jian-Guo Wei, Xiao-Feng Li, Wen-Xian Wang, Li-Xin Wu, You-cai Zhu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Gene mutation medicine.disease_cause 03 medical and health sciences 0302 clinical medicine KRAS Gene Mutation Internal medicine medicine ROS1 Crizotinib business.industry General Medicine Gene rearrangement medicine.disease ROS1 Gene Rearrangement 030104 developmental biology 030220 oncology & carcinogenesis Cancer research Adenocarcinoma KRAS business medicine.drug |
| Zdroj: | Thoracic Cancer. 9:159-163 |
| ISSN: | 1759-7706 |
| DOI: | 10.1111/1759-7714.12518 |
| Popis: | Lung adenocarcinomas with gene rearrangement in the receptor tyrosine kinase ROS1 have emerged as a rare molecular subtype. Although these lung adenocarcinomas respond to ROS1tyrosine kinase inhibitors, many patients ultimately acquire resistance. ROS1gene rearrangement is generally mutually exclusive with other driver genomic alterations, such as those in EGFR, KRAS, or ALK, thus multiple genomic alterations are extremely rare. Herein, we report a case of a 42-year-old man diagnosed with lung adenocarcinoma positive for a SDC4-ROS1 fusion, who was treated with crizotinib followed by three cycles of chemotherapy. A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients. A better understanding of the molecular biology of non-small cell lung cancer with multiple driver genomic aberrations will assist in determining optimal treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|